Skye Bioscience (NASDAQ:SKYE) Research Coverage Started at Cantor Fitzgerald

Posted by Defense World Staff on May 25th, 2024

Cantor Fitzgerald began coverage on shares of Skye Bioscience (NASDAQ:SKYE – Free Report) in a research report sent to investors on Thursday morning, MarketBeat.com reports. The firm issued an overweight rating and a $21.00 price target on the stock.

SKYE has been the topic of a number of other research reports. Piper Sandler reaffirmed an overweight rating and set a $20.00 price target (up previously from $12.00) on shares of Skye Bioscience in a research note on Thursday, March 14th. Oppenheimer assumed coverage on Skye Bioscience in a report on Friday, April 12th. They issued an outperform rating and a $25.00 price target for the company.

View Our Latest Stock Analysis on SKYE

Skye Bioscience Stock Performance

Shares of Skye Bioscience stock opened at $12.06 on Thursday. The firm has a fifty day moving average of $12.57 and a two-hundred day moving average of $10.01. Skye Bioscience has a one year low of $1.44 and a one year high of $19.41.

Skye Bioscience (NASDAQ:SKYE – Get Free Report) last released its quarterly earnings data on Friday, May 10th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). On average, equities research analysts forecast that Skye Bioscience will post -1.12 earnings per share for the current fiscal year.

About Skye Bioscience

(Get Free Report)

Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company’s lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.

Featured Articles

Receive News & Ratings for Skye Bioscience Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Skye Bioscience and related companies with MarketBeat.com’s FREE daily email newsletter.